Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efdoralprin alfa (SAR447537) vs A1PI in AATD Emphysema
NCT05856331Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 2 trial of efdoralprin alfa in alpha-1 antitrypsin deficiency (AATD), sponsored by Sanofi. Started Oct 2023; status: completed.
02
Drugs
efdoralprin alfa
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT05856331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856331.